Gilead Sciences stock at new highs, strong earnings and dividend yield.

From Zacks Investment Research: 2025-03-07 17:08:11

Gilead Sciences stock hits new highs amidst market volatility, up nearly 30% YTD at $117 per share. The company leads in HIV treatment and has a diverse drug portfolio, projecting $28.75 billion in revenue by 2024. Earnings expected to jump 70% in FY25 to $7.87 per share. Trading at 14.6X forward earnings, GILD offers a 2.65% dividend yield and is a Zacks Rank #2 (Buy) stock. With EPS estimates on the rise, investors eye Gilead as a defensive play against economic uncertainty and market turbulence.



Read more at Zacks Investment Research: Buy Gilead Sciences (GILD) Stock at 52-Week Highs? – March 7, 2025